Freeline shareholders approve acquisition by Syncona

Freeline Therapeutics and Syncona announced that Freeline’s shareholders have approved the proposal for Bidco 1354, a wholly owned subsidiary of Syncona Portfolio, to acquire all shares of Freeline not currently owned by Syncona Portfolio for $6.50 per American Depositary Share in cash. As previously announced, Freeline and Bidco entered into an implementation agreement on November 22, 2023 to implement the Acquisition by means of a scheme of arrangement pursuant to Part 26 of the UK Companies Act 2006